An oral, multi-protein Alzheimer’s/Parkinson’s bet with a 2047 patent runway—priced like failure, valued like a breakthrough if Phase 3 hits.
Overview
Annovis Bio (ANVS) is a pre-revenue, clinical-stage neurodegeneration biotech advancing buntanetap, an oral once-daily small molecule for Alzheimer’s and Parkinson’s. Its differentiated approach targets RNA translation upstream, aiming to reduce multiple aggregating neurotoxic proteins simultaneously rather than focusing on a single target like amyloid alone. The drug has been tested across 13 trials in 1,200+ patients with zero drug-related serious adverse events, positioning it as potentially safer and more scalable than infused monoclonal antibodies that carry ARIA risk and require intensive monitoring. The company is funding pivotal development through equity raises; cash runway is limited into 2026, making near-term financing and the 2027 Phase 3 readout the central catalysts.